Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.

Circulating tumor DNA (ctDNA), which carries tumor-specific mutations, is an emerging candidate biomarker for malignancies and for monitoring disease status in various human tumors. Recently, BRAF V595E mutation has been reported in 80% of dogs with urothelial carcinoma. This study investigates the...

Full description

Bibliographic Details
Main Authors: Michihito Tagawa, Naomi Tambo, Masaki Maezawa, Mizuki Tomihari, Ken-Ichi Watanabe, Hisashi Inokuma, Kazuro Miyahara
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0232365
_version_ 1818586618983874560
author Michihito Tagawa
Naomi Tambo
Masaki Maezawa
Mizuki Tomihari
Ken-Ichi Watanabe
Hisashi Inokuma
Kazuro Miyahara
author_facet Michihito Tagawa
Naomi Tambo
Masaki Maezawa
Mizuki Tomihari
Ken-Ichi Watanabe
Hisashi Inokuma
Kazuro Miyahara
author_sort Michihito Tagawa
collection DOAJ
description Circulating tumor DNA (ctDNA), which carries tumor-specific mutations, is an emerging candidate biomarker for malignancies and for monitoring disease status in various human tumors. Recently, BRAF V595E mutation has been reported in 80% of dogs with urothelial carcinoma. This study investigates the BRAF V595E allele concentration in circulating cell-free DNA (cfDNA) and assesses the clinical significance of BRAF-mutated ctDNA levels in canines with urothelial carcinoma. A total of 15 dogs with urothelial carcinoma were included. cfDNA concentration was measured using a real-time polymerase chain reaction (PCR) of the LINE-1 gene. To measure the concentration of the mutated BRAF gene in cfDNA, allele-specific real-time PCR with a locked nucleic acid probe was performed. BRAF mutations were detected in 11 (73%) of the 15 tested tumor samples. BRAF-mutated ctDNA concentrations were significantly higher in dogs with the BRAF mutation (14.05 ± 13.51 ng/ml) than in wild-type dogs (0.21 ± 0.41 ng/ml) (p = 0.031). The amount of BRAF-mutated ctDNA in plasma increased with disease progression and responded to treatment. Our results show that BRAF-mutated ctDNA can be detected using allele-specific real-time PCR in plasma samples of canines with urothelial carcinoma with the BRAF V595E mutation. This ctDNA analysis may be a potentially useful tool for monitoring the progression of urothelial carcinoma and its response to treatment.
first_indexed 2024-12-16T08:55:50Z
format Article
id doaj.art-b23092f9e06d47b788e2c966758b3fe1
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-16T08:55:50Z
publishDate 2020-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-b23092f9e06d47b788e2c966758b3fe12022-12-21T22:37:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01154e023236510.1371/journal.pone.0232365Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.Michihito TagawaNaomi TamboMasaki MaezawaMizuki TomihariKen-Ichi WatanabeHisashi InokumaKazuro MiyaharaCirculating tumor DNA (ctDNA), which carries tumor-specific mutations, is an emerging candidate biomarker for malignancies and for monitoring disease status in various human tumors. Recently, BRAF V595E mutation has been reported in 80% of dogs with urothelial carcinoma. This study investigates the BRAF V595E allele concentration in circulating cell-free DNA (cfDNA) and assesses the clinical significance of BRAF-mutated ctDNA levels in canines with urothelial carcinoma. A total of 15 dogs with urothelial carcinoma were included. cfDNA concentration was measured using a real-time polymerase chain reaction (PCR) of the LINE-1 gene. To measure the concentration of the mutated BRAF gene in cfDNA, allele-specific real-time PCR with a locked nucleic acid probe was performed. BRAF mutations were detected in 11 (73%) of the 15 tested tumor samples. BRAF-mutated ctDNA concentrations were significantly higher in dogs with the BRAF mutation (14.05 ± 13.51 ng/ml) than in wild-type dogs (0.21 ± 0.41 ng/ml) (p = 0.031). The amount of BRAF-mutated ctDNA in plasma increased with disease progression and responded to treatment. Our results show that BRAF-mutated ctDNA can be detected using allele-specific real-time PCR in plasma samples of canines with urothelial carcinoma with the BRAF V595E mutation. This ctDNA analysis may be a potentially useful tool for monitoring the progression of urothelial carcinoma and its response to treatment.https://doi.org/10.1371/journal.pone.0232365
spellingShingle Michihito Tagawa
Naomi Tambo
Masaki Maezawa
Mizuki Tomihari
Ken-Ichi Watanabe
Hisashi Inokuma
Kazuro Miyahara
Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
PLoS ONE
title Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
title_full Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
title_fullStr Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
title_full_unstemmed Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
title_short Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
title_sort quantitative analysis of the braf v595e mutation in plasma cell free dna from dogs with urothelial carcinoma
url https://doi.org/10.1371/journal.pone.0232365
work_keys_str_mv AT michihitotagawa quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT naomitambo quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT masakimaezawa quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT mizukitomihari quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT kenichiwatanabe quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT hisashiinokuma quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma
AT kazuromiyahara quantitativeanalysisofthebrafv595emutationinplasmacellfreednafromdogswithurothelialcarcinoma